Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03VHO
|
|||
Former ID |
DNC004020
|
|||
Drug Name |
Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C40H59N7O10
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=C(C=C1)OC)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
|
|||
InChI |
1S/C40H59N7O10/c1-10-25(6)33(37(51)44-32(24(4)5)38(52)56-9)45-39(53)47-46-36(50)31(21-27-16-18-29(55-8)19-17-27)43-35(49)30(20-23(2)3)42-34(48)26(7)41-40(54)57-22-28-14-12-11-13-15-28/h11-19,23-26,30-33H,10,20-22H2,1-9H3,(H,41,54)(H,42,48)(H,43,49)(H,44,51)(H,46,50)(H2,45,47,53)
|
|||
InChIKey |
QZSSZOWDSLCTPA-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
Cathepsin K (CTSK) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Lysosome | |||
Antigen processing and presentation | ||||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
IL2 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | ||||
RANKL Signaling Pathway | ||||
Reactome | Collagen degradation | |||
Trafficking and processing of endosomal TLR | ||||
Assembly of collagen fibrils and other multimeric structures | ||||
MHC class II antigen presentation | ||||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.